JP Morgan Chase & Co. (JPM.US) CEO Jamie Dimon said the spending boom in the AI sector shows no signs of slackening, with investment in the hyperscale data center ecosystem potentially reaching USD1 trillion next year, compared with estimated spending of about USD700 billion this year.

Dimon said the upsurge in spending would help juice economic growth, but could also intensify inflation as companies hire workers, build factories and power plants, and purchase equipment and materials. However, over the longer term, AI may have a deflationary effect.

When asked about returns on AI investments, Dimon said investments cannot always be measured simply by returns, adding that sometimes it is just the price of admission. He noted that improving customer experience is a benefit that is difficult to quantify, and companies may become more efficient in deploying AI over time.
~

AASTOCKS Financial News
Website: www.aastocks.com

HONG KONG, Sept. 22, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that nearly 30 clinical studies of its globally first-in-class bispecific antibodies will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress, taking place October 23–27 in Madrid, Spain. The presentations include one Late-Breaking Abstract (LBA) selected for the Presidential Symposium and two oral presentations.

Ivonescimab, the world's first approved PD-1/VEGF bispecific antibody, will be featured in 12 presentations at ESMO 2026. Notably, positive overall survival results from the Phase III HARMONi-GI1 trial evaluating ivonescimab plus chemotherapy versus durvalumab plus chemotherapy as first-line treatment for advanced biliary tract cancer have been selected as a Late-Breaking Abstract for the Presidential Symposium and will be delivered as a late-breaking oral presentation. In addition, two rapid oral presentations will present breakthrough data on ivonescimab-based regimens as first-line treatment for advanced renal cell carcinoma and recurrent/metastatic thymic carcinoma. The presentations will also highlight ivonescimab's expanding development across multiple tumor types, including continued progress in lung cancer (including brain metastases), gastrointestinal cancers (esophageal and gastric cancer), and rare or difficult-to-treat malignancies such as pancreatic cancer, glioblastoma, endometrial cancer, thymic carcinoma, and head and neck squamous cell carcinoma.

Cadonilimab, the world's first PD-1/CTLA-4 bispecific antibody, will be featured in 15 presentations covering more than ten tumor types, including gastric cancer, renal cell carcinoma, lung cancer, esophageal squamous cell carcinoma, colorectal cancer, nasopharyngeal carcinoma, ovarian cancer, soft tissue sarcoma, pleural mesothelioma, and rectal cancer. These studies span neoadjuvant settings as well as first- and second-line treatment of advanced disease, underscoring the broad anti-tumor potential of this dual checkpoint inhibitor.

The extensive data to be presented at ESMO 2026 reflect Akeso's ongoing commitment to advancing next-generation immuno-oncology therapies for major global diseases and our continued efforts to build a differentiated global oncology portfolio. Full results will be released during the Congress. Please stay tuned for updates.

Key Presentations Highlights:

LBA8 - Ivonescimab plus chemotherapy versus durvalumab plus chemotherapy as first-line treatment for advanced biliary tract cancer: a randomized, controlled, double- blinded, Phase 3 trial (HARMONi-GI1)

• Speakers: Jian Zhou (Shanghai, China)
• Session Name: Presidential Symposium II
• Room: Alicante Auditorium - Hall 6
• Date: Sunday, 25 October 2026
• Time: 16:30 - 18:15 (Madrid)

Efficacy and Safety of AK112 (Ivonescimab), a PD-1/VEGF Bispecific Antibody, as First-Line Treatment for Patients with IMDC Favorable-Risk Advanced Renal Cell Carcinoma (aRCC): Results from a Phase Ib/II Study

• Session: Rapid Oral 2: Genitourinary tumours, renal and urothelial 
• Abstract: 3592RO 
• Presentation time: Sunday, 25 October 2026, 14:45–16:15 (Madrid) 
• Presenter: Professor Xieqiao Yan, Peking University Cancer Hospital

Ivonescimab plus chemotherapy as first-line treatment in recurrent/metastatic thymic carcinoma: interim results from the iTHYM study

• Session: Rapid Oral: Non-metastatic NSCLC and other thoracic malignancies 
• Abstract: 4156RO 
• Presentation time: Monday, 26 October 2026, 10:15–11:45 (Madrid)
• Presenter: Professor Xue Hou, Sun Yat-sen University Cancer Center

About Akeso
Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, Akeso has built a comprehensive R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.

Backed by world-class GMP manufacturing facilities and a highly efficient, integrated commercialization system, Akeso has developed into a globally competitive biopharmaceutical enterprise. Leveraging its fully integrated, multi-functional platform, the Company maintains a robust pipeline of more than 50 innovative assets targeting cancer, autoimmune diseases, inflammation, metabolic disorders, and other major therapeutic areas. Of these, nearly 30 candidates have advanced into clinical trials, including 15 bispecific or multi-specific antibodies and bispecific ADCs. Eight innovative drugs are commercially available, and two additional drugs with three indications are currently under regulatory review for marketing approval.

Akeso is committed to becoming a global leader in biopharmaceuticals through efficient and breakthrough innovation in R&D, developing novel therapies that are first-in-class or best-in-class, and providing better disease solutions for patients around the world.

Forward-Looking Statements
This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the P.R. China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

A spokesperson for the Ministry of Foreign Affairs of China announced that, at the invitation of US President Donald Trump, Chinese President Xi Jinping will pay a state visit to the US from Wednesday (23rd) to Friday (25th).

Trump will purportedly host a state dinner for Xi at the White House. US corporate leaders expected to attend include Microsoft Corporation (MSFT.US) CEO Satya Nadella, Apple Inc. (AAPL.US) Executive Chairman Tim Cook, NVIDIA Corporation (NVDA.US) CEO Jensen Huang, OpenAI CEO Sam Altman, and QUALCOMM Incorporated (QCOM.US) CEO Cristiano Amon.
~

AASTOCKS Financial News
Website: www.aastocks.com

Following earlier market talks that a Tesla, Inc. (TSLA.US) team conducted factory audits in Ningbo to pave the way for mass production of Optimus, The Paper cited sources as saying that Tesla's robotics team started factory audit work last week at supply chain companies including TUOPU GROUP (601689.SH), SANHUA (02050.HK) and JOYSON ELEC (00699.HK).

These companies primarily supply core electromechanical components such as joint modules, actuators and precision structural parts. Before Tesla's latest factory audits, the above-mentioned companies had already secured orders related to Tesla humanoid robots, although the order sizes differed, report told.

Moreover, Tesla's factory audit work was not limited to Ningbo as rumored online, sources divulged. This round of visits by Tesla's robotics team also covered supply chain companies in Yangtze River Delta areas including Hangzhou and Shanghai.
~

AASTOCKS Financial News
Website: www.aastocks.com

NVIDIA Corporation (NVDA.US) CEO Jensen Huang again dismissed the AI doomsday theory, saying AI will not pose an existential risk to humanity. He said under any circumstances, 2030 will not be the end of the world, and the chance of an apocalypse is zero.

Huang has repeatedly reiterated in recent days that AI can be managed safely, but he also opposes the introduction of new regulatory measures, arguing that development in the AI industry should not slow down.

He accentuated that products should not be released before they are ready, nor should unsafe products be delivered.
~

AASTOCKS Financial News
Website: www.aastocks.com

Microsoft Corporation (MSFT.US) CEO Satya Nadella plans to attend the state banquet hosted at the White House this week for Chinese President Xi Jinping, Bloomberg, citing sources, reported.

Apple Inc. (AAPL.US) Executive Chairman Tim Cook, NVIDIA Corporation (NVDA.US) CEO Jensen Huang, OpenAI CEO Sam Altman and QUALCOMM Incorporated (QCOM.US) CEO Cristiano Amon will also attend the banquet.

Debate surrounding AI risks is boiling up in the market. Since last week, Anthropic CEO Dario Amodei has called on the entire industry to slow AI development, though technology leaders remain divided on the issue.
~

AASTOCKS Financial News
Website: www.aastocks.com

The US auto industry hopes US President Donald Trump will maintain policies that make it difficult for Chinese automakers to operate in the US, or even fully bar them from entering the US market.

According to a letter dated last Thursday and addressed to Trump reviewed by CNBC, groups representing major segments of the US auto industry, including franchised dealers, suppliers, and domestic and foreign automakers, urged the president to maintain policies and firmly shut the door on Chinese automakers selling, importing, or producing vehicles in the US.

The letter stated that the auto industry is a key pillar of America's advanced manufacturing and defense industrial base, with production capacity and a workforce capable of responding during national emergencies. Once this foundation is hollowed out, it cannot be rebuilt in a short period of time.
~

AASTOCKS Financial News
Website: www.aastocks.com

AI startup Manus, whose acquisition by Meta Platforms, Inc. (META.US) was previously halted by the Chinese government, is conducting a fundraising round and studying financing options including a future listing in Hong Kong, the Wall Street Journal, citing sources, reported.

Manus is reportedly in talks with potential investors including investment firms IDG Capital and Boyu Capital for a financing round of about USD500 million, valuing the company at approximately USD4 billion.

Existing investors including TENCENT (00700.HK), HongShan and ZhenFund are weighing participation in the financing round, while CATL (03750.HK) had also discussed investing in Manus, sources said.

Manus currently focuses most of its operations in Singapore and is evaluating restructuring plans to pave the way for a future Hong Kong IPO, report told.
~

AASTOCKS Financial News
Website: www.aastocks.com

HONG KONG, Sept. 20, 2026 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor" or the "Company"; Stock Code: 1833.HK) recently unveiled its new product "Ping An GlobalCare" (平安跨境康) at the Shenzhen Sci-Tech Innovation Exhibition. Targeting the pain points expats face when seeking medical care in China — language barriers, unfamiliarity with hospital procedures, and fragmented services — Ping An GlobalCare combines an AI-powered real-time translation engine with a closed loop of online and offline medical services to provide one-stop patient navigation. The product is now available for trial experience in Shenzhen.

On the technology front, Ping An GlobalCare is equipped with an advanced AI-powered translation engine that supports real-time, two-way speech and text translation across 19 languages, with precise coverage of professional medical terminology, effectively removing communication barriers between patients and physicians. To suit the habits of international users, the product supports login with mobile numbers from 198 countries and regions worldwide, greatly enhancing the convenience and reach of the service.

Beyond technology, the product also emphasizes companionship throughout the entire care journey, delivering a one-stop closed loop of "online assessment → transfer by a dedicated case coordinator → end-to-end in-person escort." Take Michael, an American user who suffered sudden abdominal pain, as an example: after completing an online consultation with real-time AI translation through the system, he was promptly provided with a dedicated vehicle transfer, and a dedicated coordinator accompanied him throughout his hospital visit, shortening the normally cumbersome medical visit process to just three hours.

As for the medical team, the family doctor service team of Ping An GlobalCare has obtained membership certification under PKU Healthcare. Its service system has earned certification from three leading authorities: the World Organization of Family Doctors (WONCA), the Chinese Society of General Practice of the Chinese Medical Association (CMA), and The Royal Australian College of General Practitioners (RACGP), bringing diagnostic and treatment standards fully in line with international benchmarks. Many of its team members come from 3A hospitals in mainland China, ensuring professional and high-standard medical services.

A representative of Ping An Good Doctor said that Ping An GlobalCare represents an innovative endeavor by the Company to address the medical service needs of expatriates in China. Looking ahead, the Company will continue to strengthen its cross-border healthcare capabilities and further enrich Ping An's "online, in-hospital, at-home and corporate" service network, contributing to the development of a multi-tiered health service system and providing users at home and abroad with even more worry-free, time-saving, and money-saving full-cycle health management services.

Apple Inc. (AAPL.US) plans to launch Apple Pay service in India next month, with Axis Bank serving as its first banking partner, Reuters, citing sources, reported.

Apple reportedly plans to roll out Apple Pay in phases in India, with the initial launch supporting Axis Bank credit cards first.

The company will gradually add more banking partners and is currently in talks with other major private banks, including HDFC Bank and ICICI Bank, although commercial terms with those banks have yet to be finalized.
~

AASTOCKS Financial News
Website: www.aastocks.com